Dyne Therapeutics, Inc. $DYN Stock Bought by CenterBook Partners LP

CenterBook Partners LP grew its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 167.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 57,650 shares of the company’s stock after purchasing an additional 36,112 shares during the quarter. CenterBook Partners LP’s holdings in Dyne Therapeutics were worth $929,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Dyne Therapeutics in the 2nd quarter valued at $275,500,000. Jupiter Topco LLC acquired a new position in Dyne Therapeutics in the second quarter valued at $266,634,000. Perceptive Advisors LLC grew its holdings in shares of Dyne Therapeutics by 34.2% during the first quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock worth $84,646,000 after purchasing an additional 1,189,895 shares during the last quarter. Orbimed Advisors LLC grew its holdings in shares of Dyne Therapeutics by 32.5% during the first quarter. Orbimed Advisors LLC now owns 2,917,884 shares of the company’s stock worth $52,901,000 after purchasing an additional 715,700 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in shares of Dyne Therapeutics during the second quarter worth about $49,604,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of DYN opened at $17.92 on Wednesday. Dyne Therapeutics, Inc. has a fifty-two week low of $14.00 and a fifty-two week high of $27.31. The company has a market capitalization of $3.36 billion, a price-to-earnings ratio of -4.94 and a beta of 1.22. The firm has a 50-day simple moving average of $17.42 and a 200-day simple moving average of $19.34. The company has a debt-to-equity ratio of 0.21, a quick ratio of 12.99 and a current ratio of 12.99.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.15). During the same quarter in the previous year, the business posted ($0.76) earnings per share. On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.77 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Oppenheimer downgraded Dyne Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $40.00 to $15.00 in a report on Wednesday, October 28th. HC Wainwright dropped their price target on Dyne Therapeutics from $50.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, September 30th. Jefferies Financial Group reaffirmed a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, September 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Thursday, October 15th. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $31.29.

Insider Buying and Selling

In related news, CEO John Cox sold 5,658 shares of Dyne Therapeutics stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the transaction, the chief executive officer directly owned 357,507 shares in the company, valued at $6,749,732.16. This trade represents a 1.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Brian S. Posner acquired 2,500 shares of the company’s stock in a transaction on Friday, October 2nd. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $40,000.00. Following the completion of the purchase, the director directly owned 27,000 shares in the company, valued at $432,000. This trade represents a 10.20% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold 2,598,706 shares of company stock worth $65,432,671 over the last three months. 9.46% of the stock is owned by company insiders.

Key Headlines Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $32 price target. It also raised its Q4 2026 EPS estimate to a loss of $0.95 per share from $1.01, a modest improvement. Dyne Therapeutics analyst estimates
• Neutral Sentiment: A short-interest update reported zero shares sold short and a 0.0-day short-interest ratio, despite describing short interest as having increased significantly. The figures are contradictory, so they offer little reliable indication of investor positioning.
• Negative Sentiment: HC Wainwright lowered its projected EPS for FY2027, FY2028 and FY2029, implying larger expected losses in those years. Its FY2026 estimate also edged lower; the company is expected to remain loss-making. Dyne Therapeutics analyst estimates

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.